- What other names is Passion Flower known by?
- What is Passion Flower?
- How does Passion Flower work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for Passion Flower.
Apricot Vine, Burucuya, Corona de Cristo, Fleischfarbige, Fleur de la Passion, Fleur de Passiflore, Flor de Passion, Granadilla, Grandilla, Grenadille, Madre Selva, Maracuja, Maypop, Maypop Passion Flower, Pasiflora, Pasionari, Pasionaria, Passiflora, Passiflora incarnata, Passiflorae Herba, Passiflore, Passiflore Aubépine, Passiflore Officinale, Passiflore Purpurine, Passiflore Rouge, Passiflorina, Passion Vine, Passionaria, Passionblume, Passionflower Herb, Passionsblomma, Passionsblumenkraut, Purple Passion Flower, Water Lemon, Wild Passion Flower.
Passion flower is a climbing vine that is native to the southeastern United States, and Central and South America. It was used as a food plant and in traditional medicine as a sedative. The above ground parts are used to make medicine.
Passion flower is taken by mouth for sleep problems (insomnia), anxiety, adjustment disorder, indigestion, pain, fibromyalgia, muscle cramps, diarrhea, relieving symptoms related to narcotic drug withdrawal, and reducing anxiety and nervousness before surgery.
Passion flower is also taken by mouth for seizures, asthma, symptoms of menopause, premenstrual symptoms, menstrual cramps, attention deficit-hyperactivity disorder (ADHD), palpitations, irregular heartbeat, and heart failure.
In foods and beverages, passion flower extract is used as a flavoring.
In 1569, Spanish explorers discovered passion flower in Peru. They believed the flowers symbolized Christ's passion. Passionflower was formerly approved as an over-the-counter sedative and sleep aid in the U.S., but this approval was withdrawn in 1978 when the U.S. Food and Drug Administration (FDA) reviewed the class and manufacturers did not submit evidence of safety and effectiveness.
Possibly Effective for...
- Anxiety. Some research shows that taking passion flower by mouth can reduce symptoms of anxiety. In fact, it might work as effectively as some prescription medications.
- Anxiety before surgery. Some research shows that taking passion flower by mouth can reduce anxiety before surgery when taken 30-90 minutes before surgery.
Insufficient Evidence to Rate Effectiveness for...
- A psychiatric disorder known as "adjustment disorder with anxious mood." . When used in a multi-ingredient product (Euphytose, EUP), passion flower might help reduce symptoms associated with adjustment disorder with anxious modd. Other herbs in the product are crataegus, ballota, and valerian, which have mild sedative effects, and cola and paullinia, which have stimulant effects. It's not clear which ingredient or ingredients in the mix are responsible for decreasing anxiety in people with this condition.
- Attention deficit-hyperactivity disorder (ADHD). Early research suggests that passion flower reduces some symptoms of ADHD in children aged 6-13 years when taken by mouth for 8 weeks.
- Heart failure. Early research shows that taking a combination of passion flower and hawthorn by mouth for 6 weeks increases six-minute walking distance but not exercise capacity during a bicycle exercise in people with mild heart failure.
- Trouble sleeping (insomnia). Early research suggests that drinking a passionflower tea an hour before bedtime for 7 nights improves people's ratings of their sleep quality. Also, taking a product containing passion flower, valerian, and hops (NSF-3 by M/s Tablets India) by mouth for 2 weeks improves sleep similar to zolpidem in people with insomnia.
- Narcotic drug withdrawal. Early research suggests that taking a passion flower extract in addition to a drug called clonidine for 14 days might reduce anxiety symptoms better than taking clonidine alone in people undergoing a narcotic detoxification program.
- Heart problems.
- Other conditions.
The chemicals in passion flower have calming and sleep-inducing effects.
Passionflower is LIKELY SAFE for most people when used in food-flavoring amounts. It is POSSIBLY SAFE when taken as a tea nightly for 7 nights, or as a medicine for up to 8 weeks. It is POSSIBLY UNSAFE when taken by mouth in large amounts, such as 3.5 grams of a specific extract (Sedacalm, Bioplus Healthcare, Australia) over a 2-day period.
There isn't enough information to rate the safety of passionflower when applied to the skin.
Special Precautions & Warnings:Pregnancy and breast-feeding: Don't take passionflower if you are pregnant. It is POSSIBLY UNSAFE. There are some chemicals in the passion flower plant that might cause the uterus to contract.
Not enough is known about the safety of taking passionflower during breast-feeding. Stay on the safe side and don't use it.
Surgery: Passionflower can affect the central nervous system. It might increase the effects of anesthesia and other medications on the brain during and after surgery. Stop taking passionflower at least 2 weeks before a scheduled surgery.
Sedative medications (CNS depressants)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Passionflower might cause sleepiness and drowsiness. Medications that cause sleepiness are called sedatives. Taking passionflower along with sedative medications might cause too much sleepiness.
The following doses have been studied in scientific research:
- For anxiety: Capsules containing 400 mg of passion flower extract twice daily for 2-8 weeks has been used. Also, 45 drops of a liquid extract of passion flower has been used daily for 4 weeks.
- For reducing anxiety before surgery: 20 drops of a specific passion flower extract (Pasipay by Iran Darouk Pharmaceutical Company) taken the evening before surgery and 90 minutes before the start of surgery has been used. Tablets of this product have also been used in a dose of 500 mg taken 90 minutes before the start of surgery. Also, 5 mL of syrup containing 700 mg of passion flower extract (Passiflora syrup by Sandoz) has been taken 30 minutes before surgery.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Brown, E., Hurd, N. S., McCall, S., and Ceremuga, T. E. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA.J 2007;75(5):333-337. View abstract.
Dhawan, K., Kumar, S., and Sharma, A. Comparative biological activity study on Passiflora incarnata and P. edulis. Fitoterapia 2001;72(6):698-702. View abstract.
Gerhard, U., Hobi, V., Kocher, R., and Konig, C. [Acute sedatiing effect of a herbal tranquilizer compared to that of bromazepam]. Schweiz.Rundsch.Med.Prax. 12-27-1991;80(52):1481-1486. View abstract.
Nassiri-Asl, M., Shariati-Rad, S., and Zamansoltani, F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC.Complement Altern Med 2007;7:26. View abstract.
Rickels, K. and Hesbacher, P. T. Over-the-counter daytime sedatives. A controlled study. JAMA 1-1-1973;223(1):29-33. View abstract.
Smith, G. W., Chalmers, T. M., and Nuki, G. Vasculitis associated with herbal preparation containing Passiflora extract. Br J Rheumatol. 1993;32(1):87-88. View abstract.
Soulimani, R., Younos, C., Jarmouni, S., Bousta, D., Misslin, R., and Mortier, F. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. J Ethnopharmacol. 1997;57(1):11-20. View abstract.
Von Eiff M, Brunner H, Haegeli A, and et al. Hawthorn / passion flower extract and improvement in physical exercise capacity of patients with dyspnoea Class II of the NYHA functional classifications. Acta Therapeutica 1994;20:47-66.
Wolfman, C., Viola, H., Paladini, A., Dajas, F., and Medina, J. H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 1994;47(1):1-4. View abstract.
Yaniv, R., Segal, E., Trau, H., Auslander, S., and Perel, A. Natural premedication for mast cell proliferative disorders. J Ethnopharmacol. 1995;46(1):71-72. View abstract.
Akhondzadeh S, Kashani L, Mobaseri M, et al. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 2001;26:369-73. View abstract.
Akhondzadeh S, Mohammadi MR, Momeni F. Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy 2005;2(4):609-14.
Akhondzadeh S, Naghavi HR, Shayeganpour A, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001;26:363-7. View abstract.
Ansseau M, Seidel L, Crosset A, Dierckxsens Y, Albert A. A dry extract of Passiflora incarnata L. (Sedanxio) as first intention treatment of patients consulting for anxiety problems in general practice. Acta Psychiatrica Belgica 2012;112(3):5-11.
Aoyagi N, Kimura R, Murata T. Studies on passiflora incarnata dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol. Chem Pharm Bull 1974;22:1008-13. View abstract.
Appel K, Rose T, Fiebich B, et al. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res 2011;25:838-43. View abstract.
Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth 2012;26(1):39-44. View abstract.
Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study vs placebo. Fundam Clin Pharmacol 1997;11:127-32. View abstract.
Capasso A., Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination. Phytomedicine. 2005;12:39-45. View abstract.
Carrasco MC, Vallejo JR, Pardo-de-Santayana M, et al. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009 Dec;23:1795-6. View abstract.
Code of Federal Regulations Title 21, Chapter 1, Subchapter B, section 172.510: Natural flavoring substances and natural substances used in conjunction with flavors. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=172.510 (accessed 02/22/16).
Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol 2001;78:165-70.. View abstract.
Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia 2001;72:922-6.. View abstract.
Farnsworth N, Bingel A, Cordell G, et al. Potential value of plants as sources of new antifertility agents I. J Pharm Sci 1975;64:535-98. View abstract.
Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol 2000;38:63-6. View abstract.
Foster S, Tyler VE. Tyler's Honest Herbal, 4th ed., Binghamton, NY: Haworth Herbal Press, 1999.
Gralla EJ, Stebbins RB, Coleman GL, Delahunt CS. Toxicity studies with ethyl maltol. Toxicol Appl Pharmacol 1969;15:604-13. View abstract.
Grundmann O, Wang J, McGregor GP, Butterweck V. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Medica 2008;74:1769-73. View abstract.
Kaviani N, Tavakoli M, Tabanmehr M, Havaei R. The efficacy of Passiflora incarnata Linnaeus in reducing dental anxiety in patients undergoing periodontal treatment. J Dent (Shiraz) 2013;14(2):68-72. View abstract.
Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian J Pharmacol 2013;45(1):34-9. View abstract.
Medina JH, Paladini AC, Wolfman C, et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 1990;40:2227-31. View abstract.
Miroddi M, Calapai G, Navarra M, et al. Passiflora incarnata L: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol 2013;150:791-804. View abstract.
Miyasaka LS, Atallah AN, Soares BG. Passiflora for anxiety disorder. Cochrane Database Syst Rev 2007;(1):CD004518. View abstract.
Mori A, Hasegawa K, Murasaki M, et al. Clinical evaluation of Passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam. Rinsho Hyoka (Clinical Evaluation) 1993;21:383-440.
Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2008;106:1728-32. View abstract.
Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (Passionflower) herbal tea on subjective sleep quality. Phytother Res 2011;25:1153-9. View abstract.
Patel SS, Mohamed Saleem TS, Ravi V, et al. Passiflora incarnata Linn: a phytopharmacological review. Int J Green Pharmacy 2009;Oct-Dec:277-80.
Rommelspacher H, May T, Salewski B. (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol 1994;252:51-9.. View abstract.
Salgueiro JB, Ardenghi P, Dias M, et al. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol Biochem Behav 1997;58:887-91. View abstract.
Speroni E., Minghetti A. Neuropharmacological activity of extracts from Passiflora incarnata. Planta Med. 1988;54:488-91. View abstract.
Von Eiff M, Brunner H, Haegeli A, et al. Hawthorn / passion flower extract and improvement in physical exercise capacity of patients with dyspnoea Class II of the NYHA functional classifications. Acta Therapeutica 1994;20:47-66.